KRAS mutations are notorious drivers in approximately 30% of all human cancers, with an overwhelming 90% incidence in pancreatic ductal adenocarcinoma (PDAC), a malignancy characterized by dismal prognosis and limited treatment options. KRAS inhibitors have been hailed as potential game-changers, yet their clinical efficacy is frequently undermined by acquired drug resistance. This research addresses a critical gap: the role of metabolic rewiring and mitochondrial quality control, particularly mitophagy, in mediating resistance to KRAS-targeted therapies.

The study centers on the observation that KRAS inhibitors, specifically MRTX1133 targeting the KRAS(G12D) mutant and the pan-RAS inhibitor RMC-6236, lead to a significant reduction in ATP citrate lyase (ACLY) expression and consequently decrease cytosolic AcCoA levels in both murine KPC cells and human PDAC AsPC-1 cells harboring KRAS(G12D) mutations. This metabolic suppression initiates a cascade culminating in elevated mitophagy, a selective autophagic process for mitochondrial turnover. Importantly, the induction of mitophagy by KRAS inhibition was effectively antagonized by exogenous acetate supplementation, underscoring the centrality of the ACLY-AcCoA axis in controlling this process.

Delving deeper, the researchers demonstrated that mitophagy triggered by KRASi is strikingly dependent on NLRX1, a mitochondrial NOD-like receptor previously implicated in innate immune signaling and mitochondrial homeostasis. NLRX1-deficient cells exhibited a near-complete abrogation of KRASi-induced mitophagy, illuminating its indispensable role as a mediator of mitochondrial quality control in this context. The absence of NLRX1 not only hindered mitophagy but also resulted in pronounced accumulation of reactive oxygen species (ROS) and heightened cellular oxidative stress, as evidenced by increased NADP⁺/NADPH ratios.

The functional consequences of these molecular events were profound. NLRX1 deficiency sensitized cancer cells to KRAS inhibition, augmenting cytotoxicity in both murine and human KRAS-mutant PDAC and lung cancer models. This finding was further bolstered by experiments involving the antioxidant N-acetyl-L-cysteine (NAC), which rescued the viability of NLRX1-deficient cells exposed to KRASi by mitigating oxidative stress. It became evident that the mitophagy pathway represents a cellular defensive maneuver that mitigates ROS-induced damage to sustain tumor cell survival during KRAS-targeted therapy.

Complementing the in vitro analyses, in vivo studies employing a subcutaneous KPC tumor model in NSG mice cemented the therapeutic relevance of the ACLY–AcCoA–NLRX1 axis. Mice receiving the KRAS inhibitor MRTX1133 exhibited notable tumor regression, an effect amplified in the absence of NLRX1. Moreover, immunoblot and histological analyses revealed that while Acly suppression occurred uniformly across conditions, mitochondrial protein levels—indicative of mitophagy—were preserved in NLRX1-deficient tumors, affirming the disrupted mitophagic response. Consistently, ROS levels were reduced in control tumors following KRASi but escalated in NLRX1-lacking specimens, reinforcing the interplay between mitophagy, redox balance, and therapy resistance.

These revelations shift the paradigm by identifying mitophagy not merely as a housekeeping process but as a vital resistance mechanism exploited by cancer cells under pharmacologic assault. The study’s insights suggest that targeting the metabolic regulation of mitophagy—specifically through the ACLY-AcCoA-NLRX1 signaling axis—may enhance the efficacy of KRAS inhibitors and suppress tumor adaptation.

Intriguingly, this research also reports synergistic antitumor effects when combining KRAS inhibitors with mitophagy inhibitors like Mdivi-1, which exacerbates mitochondrial dysfunction and oxidative stress in cancer cells. This dual targeting strategy presents a compelling therapeutic avenue, potentially circumventing the resilience conferred by mitophagy-mediated mitochondrial clearance.

From a mechanistic viewpoint, the intimate connection between decreased ACLY activity and mitophagy induction underscores the broader concept that metabolic state functions as a signaling nexus. Cytosolic AcCoA emerges as more than a metabolic intermediate; it acts as a signaling metabolite communicating cellular energy and nutrient status to the mitophagy machinery. This axis elegantly illustrates how metabolic rewiring can intersect with organelle quality control to govern cell fate decisions during oncogenic stress.

Beyond immediate therapeutic implications, these findings raise significant questions about mitophagy’s role across diverse KRAS-mutant tumor types and contexts of therapy resistance. As chronic KRAS inhibition becomes more prevalent in clinical oncology, understanding how tumor cells engage mitochondrial quality control pathways could guide the design of combinatorial regimens that preempt or reverse resistance.

Moreover, this study highlights the vital importance of ROS homeostasis in malignancies driven by KRAS mutations. The intricate balance between mitochondrial removal and redox signaling revealed here may represent a universal vulnerability exploitable across cancers characterized by oxidative stress adaptations.

In conclusion, the elucidation of the ACLY–AcCoA–NLRX1 axis as a regulator of mitophagy in KRAS inhibitor-mediated drug resistance broadens the framework of cancer metabolism and organelle dynamics in oncogenesis. It opens exciting pathways for innovative treatments that disrupt tumor adaptive mechanisms, potentially transforming outcomes for patients afflicted with some of the deadliest KRAS-driven cancers.

Subject of Research:
KRAS-mutant cancer metabolism, mitophagy, and drug resistance mechanisms

Article Title:
Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy

Article References:
Zhang, Y., Shen, X., Shen, Y. et al. Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy. Nature (2025). https://doi.org/10.1038/s41586-025-09745-x

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41586-025-09745-x

Bladder cancer remains one of the most prevalent and deadly malignancies affecting the urinary tract, characterized by high rates of recurrence and mortality. Despite advances in clinical treatment, the molecular mechanisms underpinning its progression and interaction with the host immune environment remain incompletely understood. SLC16A7, belonging to the solute carrier family 16, encodes a class of monocarboxylate transporters responsible for the proton-coupled translocation of key metabolites such as lactate, pyruvate, and ketone bodies. These metabolites are critical for cellular metabolism and energy homeostasis, particularly within the tumor microenvironment where metabolic rewiring is a hallmark of cancer.

The team implemented a comprehensive pan-cancer analysis utilizing data from 33 distinct tumor types curated in The Cancer Genome Atlas (TCGA). This approach enabled them to systematically assess SLC16A7’s expression levels and correlate these with diverse clinical parameters including tumor stage, mutation burden, microsatellite instability (MSI), immune cell infiltration, and survival outcomes. The study revealed that SLC16A7 expression was consistently downregulated in the majority of analyzed cancers, including bladder cancer, underscoring a potential universal tumor-suppressive function that transcends cancer subtypes.

One of the most compelling findings was the dichotomous relationship between SLC16A7 expression and patient prognosis, which varied depending on the cancer type. In bladder cancer, elevated SLC16A7 levels were robustly associated with better overall survival, a finding confirmed through Kaplan-Meier survival analyses using independent patient cohorts. This prognostic association affirms the gene’s potential utility both as a diagnostic marker and a predictor of treatment response, offering clinicians a new molecular handle to stratify patient risk more accurately.

Genomic investigations further exposed significant correlations between SLC16A7 expression and tumor mutation burden (TMB) in 13 cancer types, as well as with microsatellite instability in 11 cancers. These genetic instability measures are critical in cancer biology, often affecting how tumors evolve and respond to immunotherapies. The association suggests that SLC16A7 may influence not only metabolic homeostasis but also the mutational landscape, possibly through mechanisms impacting DNA repair or cellular stress responses.

To unravel the functional implications of SLC16A7, the researchers delved into pathway analyses utilizing hallmark gene set enrichment (Hallmark-GSEA) and Kyoto Encyclopedia of Genes and Genomes (KEGG-GSEA) databases. The results illuminated strong links between SLC16A7 and pathways governing immune response and tumor progression. These pathways include those involved in T-cell activation, cytokine signaling, and inflammatory responses, implicating SLC16A7 as a key modulator within the tumor microenvironment’s complex immunological network.

Immune infiltration analyses, employing CIBERSORT computational deconvolution methods, depicted a nuanced relationship between SLC16A7 and various immune cell subtypes populating the tumor microenvironment. Notably, SLC16A7 expression positively correlated with resting memory CD4+ T cells, eosinophils, monocytes, and memory B cells, which are generally associated with immune surveillance and anti-tumor activities. Conversely, it was negatively correlated with activated memory CD4+ T cells, M1 macrophages, follicular helper T cells, and CD8+ T cells in certain cancer contexts, suggesting complex immunomodulatory roles that may vary across tumor types.

Experimental validation through in vitro and ex vivo methods confirmed the diminished expression of SLC16A7 in bladder cancer tissues and cell lines compared to normal counterparts. Functional assays demonstrated that restoring SLC16A7 expression significantly inhibited bladder cancer cell proliferation, highlighting its direct role in curbing tumor growth. Moreover, co-culture experiments with activated CD8+ T cells revealed that SLC16A7 enhances the chemotactic attraction of cytotoxic lymphocytes toward tumor cells and boosts their tumor-killing efficacy, underscoring its pivotal role in orchestrating anti-tumor immunity within the bladder cancer microenvironment.

The mechanistic insights gleaned from this study present SLC16A7 as a multifaceted tumor suppressor. By regulating metabolite transport, it appears to influence cellular energy balance and metabolic crosstalk that are essential for both cancer cell viability and immune cell functionality. The enhanced recruitment and activation of CD8+ cytotoxic T cells driven by SLC16A7 suggest it acts as a bridge linking metabolism to immune surveillance, a crucial axis in the fight against cancer.

Given the growing emphasis on immunotherapy as a transformative approach to cancer treatment, these findings have profound clinical relevance. The ability of SLC16A7 to facilitate immune cell infiltration and activation within the tumor microenvironment may enhance responses to checkpoint inhibitors and other immunomodulatory treatments. Thus, therapeutic strategies aimed at restoring or mimicking SLC16A7 functions offer an exciting avenue to potentiate existing therapies and overcome resistance mechanisms.

Beyond bladder cancer, the pan-cancer perspective of this study provides a valuable framework for understanding SLC16A7’s context-dependent roles in diverse oncological settings. Its downregulation across most cancers and association with improved survival metrics reinforce the importance of metabolic transporters as crucial regulators of tumor biology. The dual role observed – protective in some cancers, complex in others – also sheds light on the intricate tumor heterogeneity that continues to challenge precision oncology.

This research further enriches the landscape of cancer biomarker discovery by positioning SLC16A7 as a potential candidate for diagnostic panels and therapeutic targeting. Given the gene’s influence on immune modulation and tumor progression, integrating SLC16A7 expression profiling into clinical workflows could improve the granularity of patient stratification, helping to tailor treatments more effectively and avoid unnecessary therapeutic burdens.

In conclusion, the elucidation of SLC16A7’s tumor-suppressing function provides a compelling narrative linking cancer metabolism, immune regulation, and clinical outcomes. The study’s integration of large-scale bioinformatics, robust experimental models, and clinical validation exemplifies modern oncology research’s multidisciplinary approach. Moving forward, deeper mechanistic studies and clinical trials will be vital to translate these insights into tangible benefits for patients battling bladder cancer and potentially other malignancies.

With cancer incidence on the rise globally, innovative biomarkers such as SLC16A7 offer hope for earlier diagnosis, better prognostic assessments, and more effective treatments. This research underscores the necessity of exploring metabolic transporters within the tumor microenvironment as therapeutic targets, opening new frontiers in the quest to outsmart cancer’s adaptive resilience.

The findings reported here lay a foundation for future investigations into the molecular interplay between metabolism and immunity in cancer. As scientists continue deciphering the complex web of tumor-host interactions, discoveries like SLC16A7 bring us closer to personalized medicine approaches that harness the body’s own defenses while starving tumors of their metabolic lifelines.

Subject of Research: Tumor-suppressing role of SLC16A7 in bladder cancer and pan-cancer analysis involving tumor progression, immune regulation, and prognosis.

Article Title: Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis

Article References:
Xu, M., Zhou, J., Lv, J. et al. Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis. BMC Cancer 25, 932 (2025). https://doi.org/10.1186/s12885-025-14345-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14345-z